Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 9/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2103901 | 0.87 | CYP17A1 (0.45) | CYP3A4CYP17A1HRH4CYP19A1HRH3 | |
| SCHEMBL5681197 | 0.77 | CYP3A4 (0.47) | CYP3A4CYP17A1IDO1HRH4CYP19A1 | |
| SCHEMBL6678903 | 0.72 | CYP17A1 (0.40) | CYP3A4CYP17A1IDO1HRH4CYP19A1 | |
| SCHEMBL9783836 | 0.71 | CYP3A4 (0.39) | CYP3A4CYP17A1IDO1HRH4CYP19A1 | |
| SCHEMBL27453822 | 0.69 | ALDH1A1 (0.43) | CYP3A4ALDH1A1ESR1ESR2TAAR1 | |
| SCHEMBL226696 | 0.69 | TAAR1 (0.51) | HRH4CYP19A1TAAR1HRH3 | |
| SCHEMBL27617871 | 0.69 | — | — | |
| SCHEMBL14910456 | 0.68 | ESR1 (0.70) | CYP3A4ALDH1A1ESR1ESR2TAAR1 | |
| SCHEMBL35881 | 0.68 | ESR1 (0.70) | CYP3A4ALDH1A1ESR1ESR2TAAR1 | |
| SCHEMBL22051901 | 0.67 | ASIC3 (0.46) | CYP3A4CYP17A1HRH4CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981880-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | claimed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | claimed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | CRY1, GPR119, MTNR1A | CYP3A4 38/4885CYP17A1 435/4885IDO1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.